Damora Therapeutics (DMRA) Return on Invested Capital (2025 - 2026)
Damora Therapeutics posted quarterly Return on Invested Capital of 0.01% for Q1 2026, up 1.0% year-on-year from 0.01% in Q1 2025, and up 62.54% on a QoQ basis from 0.02% in Q4 2025.
Damora Therapeutics (DMRA) has 2 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.
- For the quarter ending Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.02%, down 1.0% from the prior year.
- Return on Invested Capital for Q1 2026 stood at 0.01%, up from 0.02% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.01% in Q1 2026 and bottomed at 0.02% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.01% |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |